School of Medicine
Showing 41-50 of 54 Results
-
Nathan Reticker-Flynn, PhD
Assistant Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Current Research and Scholarly InterestsTo metastasize throughout our bodies, tumors subvert and co-opt our immune systems. Our lab seeks to uncover how these processes occur and develops therapies to put a stop to them.
-
Andrew Rezvani, M.D.
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsClinical research in allogeneic hematopoietic cell transplantation
-
Maria Grazia Roncarolo
George D. Smith Professor of Stem Cell and Regenerative Medicine, Emerita
Current Research and Scholarly InterestsResearch Interests
Immunetolerance: Mechanisms underlying T-cell tolerance, induction of T-cell anergy and regulatory T cells; Immunomodulation: mAbs, proteins and low molecular weight compounds which can modulate T-cell activation; Primary immunodeficiencies: Characterization of molecular and immunological defects; Gene therapy: Gene transduction of hematopoietic cells for gene therapy in primary immunodeficiencies and metabolic diseases; Hematopoiesis: Mechanisms underlying growth and differentiation of hematopoietic stem cells; Transplantation: Immune reconstitution and T-cell tolerance after allogenic stem cell transplantation; Cytokines/Cytokine receptors: Role in regulation of immune and inflammatory responses
Clinical Interests
Primary Immunodeficiencies
Monogenic Autoimmune Disorders
Allogenic Bone Marrow Transplantation
Gene Therapy Clinical Trials
Cell Therapy Clinical Trials
Clinical Trials in Autoimmune Diseases and Organ Transplantation
Clinical Trials in Hemoglobinopathies -
Ansuman Satpathy
Associate Professor of Pathology
Current Research and Scholarly InterestsOur lab works at the interface of immunology, cancer biology, and genomics to study cellular and molecular mechanisms of the immune response to cancer. In particular, we are leveraging high-throughput genomic technologies to understand the dynamics of the tumor-specific T cell response to cancer antigens and immunotherapies (checkpoint blockade, CAR-T cells, and others). We are also interested in understanding the impact of immuno-editing on the heterogeneity and clonal evolution of cancer.
-
Liora Schultz
Clinical Assistant Professor, Pediatrics - Hematology & Oncology
BioI am currently postdoctoral research fellow pursuing immunotherapy research in the oncology department at Stanford University. My clinical training as a pediatric hematology oncology fellow at Memorial Sloan Kettering Cancer Center highlighted the desperate need for novel therapeutic options for a subtype of aggressive pediatric leukemia, Acute Myeloid Leukemia (AML). Despite our best standard of care for AML, long term survival rates range from 50-60% with an unacceptably high relapse rate of 40%. The urgent need for novel treatments inspired me to pursue a research project in adoptive immunotherapy, genetically modifying Tcells to express artificial T cell receptors, termed chimeric antigen receptors (CARs), that target AML specific antigens. In parallel to my clinical training, I constructed an AML specific CAR and demonstrated its ability to redirect T cell function mediating eradication of AML cells. As the field of CAR therapy rapidly advances, novel methods to optimize this therapeutic modality are imperative. To this end, supported by research demonstrating superior antitumor function of naïve derived effector T cells compared to central memory derived effector T cells, I am investigating whether preferential modification of naïve T cells to express CARs will generate a T cell subpopulation with increased efficacy. Consolidating my clinical and research experiences within highly academic institutes allows me to synthesize my pursuit of scientific rigor and commitment to the field of oncology, with a mission to achieve productive research and translatable results.
-
Judith Shizuru
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsTransplantation of defined populations of allogeneic hematopoietic cells. Specifically, the way in which hematopoietic cell grafts alter antigen specific immune responses to allo-, auto- and viral antigens. The cellular and molecular basis of resistance to engraftment of allogeneic hematopoietic stem cells.
-
Surbhi Sidana, MD
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
BioDr. Surbhi Sidana is an Associate Professor of Medicine at Stanford University and specializes in the treatment of multiple myeloma and related disorders. She leads the Myeloma CAR-T/Immunotherapy program at Stanford.
Dr Sidana grew up in Delhi, India, where she completed her initial medical training. She then moved to the U.S and completed her Internal Medicine Residency at Cleveland Clinic in Cleveland, Ohio, followed by Hematology/Oncology fellowship at Mayo Clinic in Rochester, MN. Following this, she completed an Advanced Hematology Fellowship in Myeloma, Amyloidosis and Related Disorders at Mayo Clinic in Rochester, MN before joining Stanford University as a faculty member in 2019, where she has led the development of the myeloma CAR-T and bispecific antibody program.
Dr Sidana has an active, broad research portfolio that includes clinical trials of novel therapies in myeloma and related disorders, translational research, epidemiologic and patient reported outcome studies. She has a special focus on research with immunotherapies such as CAR-T cell therapy and bispecific antibodies. She has published over 80 research manuscripts. Dr Sidana is the Leader of the Myeloma Disease Focused Group and the Associate Director for Clinical Research in the BMT and Cell Therapy Division at Stanford University. She also co-leads a multi-institutional collaboration on real world outcomes with immunotherapies in myeloma.
Dr Sidana is actively involved in and holds leadership positions in national and international professional societies. She co-chairs the Quality-of-Life Committee of the International Myeloma Working Group and is the Vice-Chair of the American Society of Hematology Committee on Communications. She also a member of the ASH Editor Search Committee and the SWOG Myeloma Committee. -
Melody Smith, MD, MS
Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
BioDr. Smith is a board-certified, fellowship-trained medical oncologist and hematologist. She is an assistant professor in the Department of Medicine in the Division of Blood & Marrow Transplantation and Cellular Therapy.
She is also a physician-scientist who conducts extensive research. As a medical student, she completed a fellowship at the National Institutes of Health (NIH) in the Clinical Research Training (now, the Medical Research Scholars) Program. Subsequently, following her clinical fellowship, she was a post-doctoral researcher at Memorial Sloan Kettering Cancer Center. The research in her lab focuses on investigations of the biology of chimeric antigen receptor (CAR) T cells to improve the efficacy and safety of this therapy (1) by investigating donor (Nature Medicine, 2017) and off-the-shelf CAR T cells in mouse models and (2) by assessing mechanisms for the impact of the intestinal microbiome on CAR T cell response (Nature Medicine, 2022).
Dr. Smith presents the findings of her research at regional, national, and international conferences. Further, she has co-authored articles on topics within the field of cancer immunology, including cancer immunotherapy, stem cell transplantation, and CAR T cell therapy. Her work has appeared in journals, among others Nature, Nature Immunology, Nature Medicine, Blood, and Transplantation and Cellular Therapy. She serves a peer reviewer for publications in journals, such as NEJM Evidence, Science Advances, Blood, Cancer Cell, and Molecular Therapy. She also has contributed to chapters in books, including Pocket Oncology, Current Concepts and Controversies in Hematopoietic Cell Transplantation, and Advanced Concepts in Human Immunology: Prospects for Disease Control.
She has earned numerous honors; the American Society of Hematology (ASH), the Society for Immunotherapy of Cancer, the European Society for Blood and Marrow Transplantation, and several other professional organizations have recognized her achievements as a clinician, researcher, and scholar.
Dr. Smith is a member of the ASH Committee on Emerging Gene and Cell Therapies and the ASH Committee on Diversity, Equity & Inclusion. Additionally, she serves on committees within the institution and professional organizations focused on promoting diversity among hematology and cell therapy specialists. -
John B. Sunwoo, MD
Edward C. and Amy H. Sewall Professor in the School of Medicine and Professor, by courtesy, of Dermatology
Current Research and Scholarly InterestsMy laboratory is focused on two primary areas of research: (1) the immune response to head and neck cancer and to a tumorigenic population of cells within these malignancies called cancer stem cells; (2) the developmental programs of a special lymphocyte population involved in innate immunity called natural killer (NK) cells; and (3) intra-tumor and inter-tumor heterogeneity.
-
Robert Waymouth
Robert Eckles Swain Professor of Chemistry and Professor, by courtesy, of Chemical Engineering
BioRobert Eckles Swain Professor in Chemistry Robert Waymouth investigates new catalytic strategies to create useful new molecules, including bioactive polymers, synthetic fuels, and sustainable plastics. In one such breakthrough, Professor Waymouth and Professor Wender developed a new class of gene delivery agents.
Born in 1960 in Warner Robins, Georgia, Robert Waymouth studied chemistry and mathematics at Washington and Lee University in Lexington, Virginia (B.S. and B.A., respectively, both summa cum laude, 1982). He developed an interest in synthetic and mechanistic organometallic chemistry during his doctoral studies in chemistry at the California Institute of Technology under Professor R.H. Grubbs (Ph.D., 1987). His postdoctoral research with Professor Piero Pino at the Institut fur Polymere, ETH Zurich, Switzerland, focused on catalytic hydrogenation with chiral metallocene catalysts. He joined the Stanford University faculty as assistant professor in 1988, becoming full professor in 1997 and in 2000 the Robert Eckles Swain Professor of Chemistry.
Today, the Waymouth Group applies mechanistic principles to develop new concepts in catalysis, with particular focus on the development of organometallic and organic catalysts for the synthesis of complex macromolecular architectures. In organometallic catalysis, the group devised a highly selective alcohol oxidation catalyst that selectively oxidizes unprotected polyols and carbohydrates to alpha-hyroxyketones. In collaboration with Dr. James Hedrick of IBM, we have developed a platform of highly active organic catalysts and continuous flow reactors that provide access to polymer architectures that are difficult to access by conventional approaches.
The Waymouth group has devised selective organocatalytic strategies for the synthesis of functional degradable polymers and oligomers that function as "molecular transporters" to deliver genes, drugs and probes into cells and live animals. These advances led to the joint discovery with the Wender group of a general, safe, and remarkably effective concept for RNA delivery based on a new class of synthetic cationic materials, Charge-Altering Releasable Transporters (CARTs). This technology has been shown to be effective for mRNA based cancer vaccines.
